Company Overview and News
Stop missing out on important events!
Patrys Limited (ASX:PAB) surged to a 12-month high of $0.04 on news that its drug candidate PAT‐DX1 has been shown to reduce brain tumour size in animal trials. (1-0)
Patrys Ltd (ASX:PAB) has been granted a trading halt by the ASX this morning, pending details relating to managing its continuous disclosure obligations. (1-0)
Patrys Limited (ASX:PAB) has been granted a U.S. patent for its anti-cancer candidate PAT-LM1 for use in treating colon cancer metastasis. (1-0)
Patrys Ltd's (ASX:PAB) shares have jumped 42% to $0.027 on massive volume of over 100 million shares. (1-0)
Patrys Ltd (ASX:PAB) is the most active stock on the ASX today, trading 87 million shares by 2pm, but its losing yesterday's momentum in the share price.
Patrys Ltd's (ASX:PAB) shares have continued to rally during the trading day, and are now up 200% at $0.012, with over 84 million shares changing hands.
Patrys Ltd's (ASX:PAB) shares are up 75% in morning trade at $0.007, following positive pre-clinical data for its lead drug candidate PAT-DX1, a novel first-in-class drug candidate being developed to treat a range of different cancers.